AU3696897A - Heterocyclic compounds with thrombolytic activity and their use for treating thrombosis - Google Patents

Heterocyclic compounds with thrombolytic activity and their use for treating thrombosis

Info

Publication number
AU3696897A
AU3696897A AU36968/97A AU3696897A AU3696897A AU 3696897 A AU3696897 A AU 3696897A AU 36968/97 A AU36968/97 A AU 36968/97A AU 3696897 A AU3696897 A AU 3696897A AU 3696897 A AU3696897 A AU 3696897A
Authority
AU
Australia
Prior art keywords
heterocyclic compounds
thrombolytic activity
treating thrombosis
thrombosis
treating
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU36968/97A
Other languages
English (en)
Inventor
Francoise Casadebaig
Jean-Pierre Dupin
Denis Gravier
Richard Gryglewsky
Genevieve Hou
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of AU3696897A publication Critical patent/AU3696897A/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/74—Quinazolines; Hydrogenated quinazolines with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, attached to ring carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
AU36968/97A 1996-07-12 1997-07-11 Heterocyclic compounds with thrombolytic activity and their use for treating thrombosis Abandoned AU3696897A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR9608969 1996-07-12
FR9608969A FR2750862B1 (fr) 1996-07-12 1996-07-12 Utilisation d'heterocycles diazotes fusionnes avec un systeme aromatique ou heteroaromatique pour le traitement des maladies thrombo-emboliques
PCT/FR1997/001278 WO1998002162A1 (fr) 1996-07-12 1997-07-11 Composes heterocycliques ayant une activite thrombolytique et leur utilisation pour le traitement de la thrombose

Publications (1)

Publication Number Publication Date
AU3696897A true AU3696897A (en) 1998-02-09

Family

ID=9494163

Family Applications (1)

Application Number Title Priority Date Filing Date
AU36968/97A Abandoned AU3696897A (en) 1996-07-12 1997-07-11 Heterocyclic compounds with thrombolytic activity and their use for treating thrombosis

Country Status (7)

Country Link
EP (1) EP0912180A1 (fr)
JP (1) JP2000514447A (fr)
CN (1) CN1228701A (fr)
AU (1) AU3696897A (fr)
CA (1) CA2260965A1 (fr)
FR (1) FR2750862B1 (fr)
WO (1) WO1998002162A1 (fr)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6984644B2 (en) 1997-05-28 2006-01-10 Astrazeneca Ab Treatment of skin disorders using thieno[2,3-D]pyrimidinediones
US6469014B1 (en) 1997-05-28 2002-10-22 Astrazeneca Ab Thieno[2,3-d] pyrimidinediones, their preparation and use in therapy
SE9702001D0 (sv) * 1997-05-28 1997-05-28 Astra Pharma Prod Novel compounds
ATE280171T1 (de) * 1998-12-23 2004-11-15 Bristol Myers Squibb Pharma Co Stickstoffhaltige heterobicyclen als faktor-xa- hemmer
BR0110302A (pt) 2000-04-18 2003-01-14 Agouron Pharma Compostos de pirazol para inibição de proteìnas cinase, sal e pró-droga farmaceuticamente aceitável, metabólito farmaceuticamente ativo ou sal farmaceuticamente aceitável de metabólito, composição farmacêutica, método de tratamento de condição doentia em mamìferos mediada pela atividade de proteìna cinase, método de modulação ou inibição da atividade de um receptor de proteìna cinase
EP1377576A2 (fr) 2001-03-26 2004-01-07 Novartis AG Derivee de la pyridine
CN100500679C (zh) * 2001-11-01 2009-06-17 中国人民解放军军事医学科学院毒物药物研究所 具有调节血管内皮细胞功能活性的化合物及其制备方法和用途
CN100486982C (zh) * 2001-11-02 2009-05-13 中国人民解放军军事医学科学院毒物药物研究所 具有预防和治疗血栓性疾病功能的化合物,含它们的药物组合物和它们的医药用途
AU2003253165A1 (en) * 2002-08-13 2004-02-25 Warner-Lambert Company Llc Pyrimidine fused bicyclic metalloproteinase inhibitors
GB0412769D0 (en) 2004-06-08 2004-07-07 Novartis Ag Organic compounds
TW200951139A (en) 2008-05-27 2009-12-16 Astrazeneca Ab Chemical compounds 293
US20120122889A1 (en) * 2008-12-23 2012-05-17 President And Fellows Of Harvard College Small molecule inhibitors of necroptosis
US8940742B2 (en) 2012-04-10 2015-01-27 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
US9725452B2 (en) 2013-03-15 2017-08-08 Presidents And Fellows Of Harvard College Substituted indoles and pyrroles as RIP kinase inhibitors
ES2900806T3 (es) 2013-10-04 2022-03-18 Infinity Pharmaceuticals Inc Compuestos heterocíclicos y usos de los mismos
WO2015051241A1 (fr) 2013-10-04 2015-04-09 Infinity Pharmaceuticals, Inc. Composés hétérocycliques et leurs utilisations
JP6701088B2 (ja) 2014-03-19 2020-05-27 インフィニティー ファーマシューティカルズ， インコーポレイテッド Ｐｉ３ｋ−ガンマ媒介障害の治療で使用するための複素環式化合物
US9708348B2 (en) 2014-10-03 2017-07-18 Infinity Pharmaceuticals, Inc. Trisubstituted bicyclic heterocyclic compounds with kinase activities and uses thereof
TWI698436B (zh) 2014-12-30 2020-07-11 美商佛瑪治療公司 作為泛素特異性蛋白酶７抑制劑之吡咯并及吡唑并嘧啶
MA41291A (fr) 2014-12-30 2017-11-07 Forma Therapeutics Inc Dérivés de la pyrrolotriazinone et de l'imidazotriazinone en tant qu'inhibiteurs de la protéase spécifique de l'ubiquitine n° 7 (usp7) pour le traitement d'un cancer
EP3253759A1 (fr) 2015-02-05 2017-12-13 Forma Therapeutics, Inc. Isothiazolopyrimidinones, pyrazolopyrimidinones, et pyrrolopyrimidinones, en tant qu'inhibiteurs de la protéase spécifique de l'ubiquitine 7
WO2016126926A1 (fr) 2015-02-05 2016-08-11 Forma Therapeutics, Inc. Quinazolinones et azaquinazolinones comme inhibiteurs de la protéase 7 spécifique de l'ubiquitine
JP2018504431A (ja) 2015-02-05 2018-02-15 フォーマ セラピューティクス，インコーポレイテッド ユビキチン特異的プロテアーゼ７阻害物質としてのチエノピリミジノン
US10160761B2 (en) 2015-09-14 2018-12-25 Infinity Pharmaceuticals, Inc. Solid forms of isoquinolinones, and process of making, composition comprising, and methods of using the same
WO2017161116A1 (fr) 2016-03-17 2017-09-21 Infinity Pharmaceuticals, Inc. Isotopologues de composés isoquinolinone et quinazolinone et leurs utilisations comme inhibiteurs de la kinase pi3k
US10919914B2 (en) 2016-06-08 2021-02-16 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
CA3094988A1 (fr) 2018-03-30 2019-10-03 Biotheryx, Inc. Composes de thienopyrimidinone
JPWO2021054393A1 (fr) * 2019-09-19 2021-03-25

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH02169520A (ja) * 1988-12-22 1990-06-29 Tsumura & Co 微小循環改善剤
JP2657760B2 (ja) * 1992-07-15 1997-09-24 小野薬品工業株式会社 ４−アミノキナゾリン誘導体およびそれを含有する医薬品
GB9510757D0 (en) * 1994-09-19 1995-07-19 Wellcome Found Therapeuticaly active compounds

Also Published As

Publication number Publication date
JP2000514447A (ja) 2000-10-31
FR2750862B1 (fr) 1998-10-16
CN1228701A (zh) 1999-09-15
CA2260965A1 (fr) 1998-01-22
FR2750862A1 (fr) 1998-01-16
EP0912180A1 (fr) 1999-05-06
WO1998002162A1 (fr) 1998-01-22

Similar Documents

Publication Publication Date Title
AU3696897A (en) Heterocyclic compounds with thrombolytic activity and their use for treating thrombosis
HU9702034D0 (en) Heterocyclic compounds of leukocita-adhesion-inhibitor and vla-4-antagonist activity
ZA977901B (en) Heterocyclic esters and amides.
EP1018987A4 (fr) Neocartilage et ses methodes d'utilisation
HUP0004170A3 (en) Methods and materials for treating and preventing inflammation ofmucosal tissue
PL331795A1 (en) Heterocyclic metaloprotease inhibitors
PL331856A1 (en) Heterocyclic inhibitors of metaloprotease
ZA939416B (en) Modified lipolytic enzymes and their use
PL331465A1 (en) Novel compounds and agents for treating diseases associated with triptase activity
AU4009795A (en) Heterocyclic compounds and their use
HUP0100353A3 (en) Naphtamidine derivatives with urokinase inhibitor activity
HUP9702242A3 (en) Inozitol-glykanes of inzulin-like activity
ZA939415B (en) Modified lipolytic enzymes and their use
GB9425701D0 (en) Enzyme inhibitors
HUP9700660A3 (en) Use of alpha-adrenoreceptor antagonists for the production of pharmaceuticals for profilacting and treating hyperplasia benigna prostatae
AU1766997A (en) Beta-thiopropionyl-aminoacid derivatives and their use as beta-lactamase inhibitors
NZ325587A (en) 4,5-dihydronaphth[1,2-c]isoxazoles and derivatives thereof having cns activity
AU1706295A (en) Dinitrogenated heterocyclic derivatives having aii-antagonistic activity
HK1020944A1 (en) Substituted heterocyclic benzocycloalkenes and their use as analgesically active compounds
AU1081897A (en) Heterocyclic compounds and their use
GB9623539D0 (en) Enzymes and their use
AU1439497A (en) Substituted n-aryl nitrogen heterocyclic compounds and their use as herbicides
HK1044773A1 (zh) 雜環n-丙酮基苯甲酰胺以及它們作為殺菌劑的使用
ZA9714B (en) Bioregulatory active substance method for its production and use thereof
GB9616563D0 (en) Compounds and methods

Legal Events

Date Code Title Description
MK5 Application lapsed section 142(2)(e) - patent request and compl. specification not accepted